FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk ...

FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, ...

A multicenter Japanese study of 135 patients shows robot-assisted pelvic exenteration for advanced rectal cancer achieved 98 percent complete resection with dramatically lower blood loss and no 30-day ...

New research shows that synthetic ligands for the orphan nuclear receptors NR4A1 and NR4A2 induce iron-dependent cell death ...

Tampere University Hospital (Tays) has begun offering a new form of radiotherapy to treat rectal cancer in which a high dose ...

The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

Colon cancer is a malignancy affecting the large intestine. The dMMR subtype involves defects in the DNA mismatch repair system, resulting in a higher mutation rate. According to Roche, more than one ...

Phantom GI is developing a device designed to create an ostomy under local anesthesia, potentially offering an option for ...

Tel Aviv medtech Phantom GI secures $5m seed led by Pitango HealthTech to develop PercStoma, a minimally invasive alternative to major surgical bowel ostomies.

Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to activate innate and adaptive antitumor immune responses, including in tumors that have historically responded poorly to ...

Nigerian trial is examining immunotherapy for selected patients with mismatch repair-deficient colorectal cancer …financial ...

Lessons From Teachers and Mentors in Surgery / cancer, cancer care, cancer treatment, Hassan R. Hashmi, OncoDaily, Oncology, ...